

Company Overview

Vitality Biopharma is unlocking the power of cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory conditions, such as pediatric forms of inflammatory bowel disease.

Key Near-Term Milestones

- Toxicology studies (1H 2018)
- Phase 1 clinical trials (1H 2018)
- Observational trial initiation (1H 2018)

Publicly-traded on the OTCQB

Ticker:VBIO

Financial Highlights

- Recent financing (Dec. 2017): \$1.4M in common stock & warrants

Management Team

Robert Brooke

CEO & Co-Founder

Bioengineer, Former-hedge fund analyst for >50 direct healthcare investments, Founder, cancer immunotherapy company (now known as Iovance Bio (NASDAQ:IOVA). Georgia Tech, UCLA Bioengineering.

Avtar Dhillon, MD

Chairman & Co-Founder

Chairman, Inovio Pharmaceuticals (NASDAQ:INO), Oncosec Medical and Arch Therapeutics. Former venture capitalist and family physician.

Brandon Zipp, PhD

Director, Research & Development

Scientific Co-founder

>12 years R&D experience with plant UGT enzymes and secondary metabolism products, PhD in Plant Sciences, UC Davis

Richard McKilligan, JD, MBA

Controller & Counsel

Formerly of Morgan, Lewis, & Bockius LLP, member of the CA and NY bar, former CPA. JD from Cornell, MBA from Univ. of Chicago, BS in Accounting from Univ. of Illinois.

Investment Highlights

Novel Cannabinoid Pharmaceuticals Provide Targeted Delivery, Reducing Delivery of Psychoactive THC to the Brain

Vitality has developed a proprietary new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. **Targeted delivery of cannabinoids enables therapeutic effects while eliminating THC's psychoactivity.** Currently, the intoxicating effects of THC limits the therapeutic dose that can be delivered to treat serious forms of pain and inflammation, and **especially in pediatric conditions.**

Treatment of Inflammatory Bowel Disease and Narcotic Bowel Syndrome, A Severe Form of Opiate-Induced Abdominal Pain

Independent clinical results suggest that cannabinoids will help induce remission in Crohn's disease, and that the vast majority of inflammatory bowel disease (IBD) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or pain. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.

Visiongain predicts that in 2017 drug revenues for treatment of IBD will reach \$9.6 billion. The ultimate goal of clinical treatment is to obtain complete disease control and to stop disease progression. This includes **remission of disease without use of steroids or opiates**, normalization of inflammatory markers, and also healing of the mucosal lining of the gastrointestinal tract, which typically leads to better clinical outcomes, reduced healthcare costs, and an improved quality of life.

Drug	Clinical Indications	Status
VBX-100	Inflammatory Bowel Disease (inducing remission), Irritable Bowel Syndrome, Narcotic Bowel Syndrome	Phase 1a/1b Trial to complete in 1 st half 2018
VBX-210	Inflammatory Bowel Disease (maintaining remission), Irritable Bowel Syndrome, Opiate-induced Bowel Dysfunction, C. difficile Infections, Colorectal Cancer	Preclinical
Additional Cannabinoid Formulations	Complex/Refractory or Neuropathic Pain (Substitution therapy for opioid painkillers), Huntington's disease, Multiple Sclerosis & Rare White Matter Disorders, Guillain-Barré	Observational clinical studies to initiate in 1 st Half of 2018

Find out more online:

www.vitality.bio